Celera and Merck link up on Alzheimer's:
This article was originally published in Clinica
Celera Diagnostics has joined forces with Merck & Co to identify novel targets for drug discovery and diagnostic markers related to Alzheimer's disease. Alameda, California-based Celera will conduct a functional genome scan to pinpoint novel gene variations associated with the disease, and will retain rights for diagnostic applications from the studies. Merck will receive rights for therapeutic applications from the studies in Alzheimer's disease, as well as for certain other neurological disorders. It will also fund discovery research at Celera related to the collaboration, and will make certain clinical milestone payments and pay a royalty on sales of pharmaceutical products it commercialises as a result of the study.
You may also be interested in...
South Korea’s Qurient achieves proof of concept in a Phase II study with its first-in-class antibiotic telacebec for tuberculosis and aims to file a US NDA for the orphan drug.
VMS businesses are deemed essential in Department of Homeland Security guidance that provides as basis for orders by most states and localities across the US. During an AHPA webinar, attorney Trent Norris says the federal government prefers leaving business exemptions to shut-down decisions to the states.
Company expects clinical trials to begin by September and says first batches could be available for emergency use authorization in early 2021; J&J pledges vaccine will be available to public on not-for-profit basis.